SCHEDULE: Avoro Capital Discloses 6.6% Stake in uniQure N.V.

Avoro Capital Advisors and Behzad Aghazadeh have disclosed a 6.6% beneficial ownership stake in uniQure N.V., acquired for investment purposes.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh reported beneficial ownership of 3,625,000 Ordinary Shares of uniQure N.V.
• This represents 6.6% of uniQure N.V.'s outstanding Ordinary Shares.
• The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• The percentage is calculated based on 54,748,496 Ordinary Shares outstanding as of May 6, 2025, as reported in uniQure N.V.'s Quarterly Report on Form 10-Q.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a specialized investment fund (Avoro Capital Advisors) in uniQure N.V. is generally viewed positively as it signals confidence in the company's prospects and potential for value appreciation, even if it's a passive investment.

Positives

• A specialized investment firm, Avoro Capital Advisors, and its controlling person, Behzad Aghazadeh, have taken a significant 6.6% stake in uniQure N.V., signaling confidence in the company's investment potential.
• The acquisition was made for investment purposes, indicating a belief in long-term value rather than short-term trading.

Negatives

• No specific negative information about uniQure N.V. is disclosed in this beneficial ownership filing.

Risks

• The shares were not acquired for the purpose of changing or influencing control of uniQure N.V., which might limit potential activist investor upside or strategic shifts driven by this new shareholder.

Future Outlook

NA

Management Comments

• The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

uniQure N.V. operates in the biotechnology sector, specifically focused on gene therapy. The acquisition of a significant stake by Avoro Capital Advisors, a firm specializing in life sciences investments, suggests a strategic interest within this specialized and often high-growth industry segment.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable investment firm could increase investor confidence and potentially influence share price positively.
• Company Management: Awareness of a new significant shareholder, though passive, may influence strategic considerations.

Key Dates

Recommendation

The filing indicates a significant passive investment by a specialized fund, Avoro Capital Advisors, in uniQure N.V. While this signals confidence from a sophisticated investor, the filing itself does not provide new operational or financial data about uniQure N.V. that would warrant a 'buy' or 'sell' recommendation. It primarily confirms a notable ownership position. Investors should 'hold' and monitor uniQure's fundamental performance and future disclosures, as this filing alone doesn't change the underlying investment thesis but adds a layer of institutional interest.

Keywords

uniQure N.V., Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, Schedule 13G, Biotechnology, Gene Therapy, Investment, Equity Stake, N90064101